key: cord-0988335-mj8wjaal
authors: Madan, Kaushal; Rastogi, Ruchi; Bhargava, Richa; Dagar, Vineeta; Singla, Vikas; Sahu, Amit; Singh, Pankaj; Garg, Pallavi; Aggarwal, Bharat; Singh, Ramkrishna Kumar
title: Is Fatty Liver associated with increased mortality and morbidity in patients with COVID-19 pneumonia?
date: 2022-04-20
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2022.04.013
sha: 8a86be8ef5b01b5c95d39e1f024efb678dff5d39
doc_id: 988335
cord_uid: mj8wjaal

BACKGROUND: Fatty liver has been shown to be associated with severe COVID-19 disease without any impact on mortality. This is based on heterogenous criteria for defining both fatty liver as well as the severity parameters. AIM: To study the impact of fatty liver on the mortality and severity of disease in patients with COVID-19 pneumonia. METHODS: In a case control study design, patients with COVID-19 pneumonia (COVID-19 CT severity index on HRCT chest of >1) with fatty liver (defined as liver to spleen attenuation index < 5 on non-contrast CT cuts of upper abdomen) were compared to those without fatty liver. The primary outcome measure was in-hospital mortality and secondary outcome measures were CTSI score need for ICU care, need for ventilatory support, duration of ICU stay and duration of Hospital stay. RESULTS: 289 (64.7%) of 446 patients with COVID-19 pneumonia admitted to Max Hospital, Saket, India, between 1/1/2021 and 30/10/2021 had fatty liver. 59 of 446 patients died during the index admission. In-hospital mortality was not different between patients with fatty liver [38 1(3.24%)] or without fatty liver [21 (13.81%)]. COVID-19 CTSI score was found to be significantly higher among patients who had fatty liver [13.40 (5.16) vs 11.81 (5.50); p= 0.003]. There was no difference in the requirement of ICU [94 (32%) vs 62 (39.49%); p=0.752], requirement of ventilatory support [27 (9.34%) vs 14 (8.91%); p=0.385], duration of ICU stay [8.29 (6.87) vs 7.07 (5.71) days; p=0.208] and duration of hospital stay [10.10 (7.14) vs 10.69 (8.13) days; p=0.430] between the groups with fatty liver or no fatty liver. Similarly, no difference was found in primary or secondary outcomes measure between the group with severe fatty liver vs mild/moderate or no fatty liver. High Total leucocyte count and FIB-4 index were independently associated with mortality. CONCLUSIONS: Fatty liver may not be associated with increased mortality or clinical morbidity of patients who have COVID-19 pneumonia.

Introduction & background.

The Pandemic of COVID-19 has led to significant morbidity and mortality across the world, since the early part of 2020. The Severe acute respiratory syndrome Corona virus-2 (SARS CoV-2) primarily affects the respiratory system and most deaths are related to the severe viral pneumonia and respiratory failure. However, other organ systems also seem to get affected to a variable degree. Patients who have underling co-morbidity seem to be more predisposed to worst outcomes. Almost 1/3 rd to 3/4 th of patients with COVID- 19 have been reported to have some degree of liver injury at the time of presentation. 1, 2 Due to this, patients with pre-existing liver disease, especially those with cirrhosis have been reported to develop decompensation and even death when they acquire infection with SARS-CoV-2. 3 The risk is higher in patients who have more advanced liver disease at the time of getting infected. 4, 5 . A number of earlier studies have presented data suggesting that the COVID-19 disease is either severe 6,7,8,9 or progressive 10 Radiological criteria or past history of presence of NAFLD or hepatic steatosis index 12 ), which makes the results difficult to compare. Even the stage of COVID-19 was not clearly defined and they included patients ranging from mild to severe disease. In some studies, the presence of non-invasively measured advanced liver fibrosis was found to be more strongly associated with adverse outcomes. 13 So, we carried out a study comparing the outcomes in clearly defined cases of fatty liver with COVID-19 pneumonia (the most severe form of COVID-19 illness).

It was a retrospective observational case control study Patients with known history of underlying cirrhosis, liver cancer, congestive cardiac failure and those with a CTSI score of <1 were excluded.

HRCT chest of patients done, between 1 st January 2021 -30 th October 2021, with a suspected diagnosis of COVID-19 pneumonia, SARS CoV-2 infection, viral pneumonia were retrieved from the picture archiving and communication system (PACS) of Max Smart Super Speciality Hospital and Max Super Speciality Hospital, Saket.

Data of COVID-19 CTSI score, and the CT attenuation difference between the liver and spleen on non-contrast upper abdominal cuts of the CT scan, were recorded.

Demographic data and laboratory data including, Complete blood count, Liver Function test, Renal Function Test, Lipid profile, serum LDH, CRP, D-dimer, Serum Ferritin, HBsAg, Anti HCV, were recorded from the electronic health records.

Non-invasive assessment of liver fibrosis was done using theFIB-4 index which was calculated as per the standard formula incorporating the values of age, AST, ALT and Platelets. 14

Fatty liver was defined as the Liver attenuation index (LAI) of <5, in the non-enhanced scans of the upper abdomen (retrieved as part of the HRCT chest). LAI was calculated as the attenuation difference between the liver and spleen on a non-contrast enhanced CT scan of upper abdomen. 15 Patients were further sub grouped in to:

Mild to moderate fatty liver: LAI between: minus10 to 5

Severe fatty liver: LAI :< minus 10 Primary outcome measure:

Mortality rates of patients with COVID-19 pneumonia with underlying fatty liver

Severity of patients with COVID-19 pneumonia with underlying fatty liver. Parameters studied for severity were: COVID-19 CTSI, need for ICU admission, need for Ventilatory support, length of ICU stay and length of hospital stay.

Patients were followed up till discharge from the hospital or till death during the index hospital admission.

A sample size of 240 in each group, was calculated to detect a difference in mortality of 10% at 5% significance level and 80% power, based on the reported mortality in the groups with and without steatosis π1, π2 = 0.226 and 0.152, respectively. 16 J o u r n a l P r e -p r o o f

The results are presented as mean (SD) for normally distributed and median (range) for skewed continuous data and proportions for categorical data. The cases with fatty liver were compared with the controls without fatty liver by Student t-test for quantitative characteristics, and by chi-square test for qualitative characteristics. For the variables with highly skewed distribution, Mann-Whitney test was used. The significance level was fixed at 5% and SPSS, version 21 was used for calculations.

The study was reviewed and approved by the Institutional Ethics Committee and a waiver of 

There was no difference in the baseline demographic and laboratory parameters between the group with fatty liver or no fatty liver (table 1) Table 2 )

In a sensitivity analysis, patients with COVID-19 pneumonia with severe fatty liver (n=78)

were compared with the group with mild fatty liver or no fatty liver (n=368). The patients with severe fatty liver were younger, less likely to be hypertensive and they had significantly more liver injury as seen by higher median AST levels [53.50 (table 3) . Despite these differences, the mortality between the two groups was not different [10 (12.98%) vs 49 (13.53%) died; p=0.898]. Like in the group with fatty liver, patients with severe fatty liver also had higher mean COVID-19 CTSI score [14.08(5.03) vs 12.58 (5.37); p=0.024]. (Table   4 ).

In order to assess the impact of presence of advanced liver fibrosis (using a non-invasive Factors associated with in-hospital mortality (Table 5) 59 patients with COVID-19 Pneumonia died in the hospital with a mortality rate of 13.22%.

On univariate analysis, the factors associated with mortality were, the presence of diabetes, presence of hypertension, Low BMI, Low Hb, high TLC, LDH, ALT, high FIB-4 index, and higher COVID-19 CTSI score. On multivariable logistic regression analysis, using the enter method and entering the variables found to be significant in univariate analysis, only high TLC values were independently found to be associated with in-hospital mortality. (Table 6 )

In a case control format, we demonstrated in patients with COVID-19 pneumonia, that presence of fatty liver or severe fatty liver or fatty liver with high FIB-4, was not associated with either mortality or other adverse outcomes such as need for ICU care or need for ventilatory support. 11 and it needs to be validated by more evidence for its use as a definition of fatty liver disease. We feel that using MAFLD for defining fatty liver in other extrahepatic conditions appears too premature. Furthermore, this criterion is biased towards making a diagnosis of metabolic dysfunction rather than fatty liver per se. One of the parameters for making a diagnosis of MAFLD is diabetes mellitus and there is now significant evidence suggesting the development of new onset diabetes among patients with COVID-19 which might again lead to overestimation of fatty liver. 23, 24, 25 Similarly, the parameter of elevated CRP which is used as one of the parameters to define the presence of metabolic dysfunction (within the definition of MAFLD), is also very frequently present during the course of COVID-19. 26 We, on the other hand defined fatty liver on the basis of validated radiological criterion (LAI<5) irrespective of metabolic predisposition to fatty liver. 27 The radiological criteria used for making a diagnosis of fatty liver in the current study were not affected by the current disease state (COVID-19) . So, we believe that our study more appropriately assesses the relationship between fatty liver (irrespective of its affiliation with metabolic dysfunction or etiology) and COVID-19. In order to test the robustness of the association, we also did a subgroup analysis of patients with severe fatty liver (LAI score <-10) and even in this group, no association was found with mortality or other adverse events. A recent meta-analysis also failed to demonstrate any impact of fatty liver on Mortality in COVID-19 patients. 8 Other studies have also demonstrated that factors other than NAFLD per se are associated with mortality in COVID-19 patients. A study in 61 NAFLD patients with COVID-19, demonstrated that in the NAFLD group, Male gender and high ferritin were associated with increased mortality, although NAFLD per se was not J o u r n a l P r e -p r o o f associated with adverse outcomes. 28 Few more studies have also demonstrated that only those patients with underlying cirrhosis, Alcoholic liver disease and hepatocellular carcinoma, but not NAFLD were associated with increased mortality due to COVID-19. 29, 30 A number of previous studies have shown that the presence of fatty liver is associated with more severe COVID-19 illness. 6, 7, 10, [16] [17] [18] [19] [20] [21] [22] The postulated mechanism is that patients with NAFLD also have an inflammatory milieu with elevated levels of inflammatory cytokines, 31 patients with fatty liver and COVID-19, there was increased need for intubation and vasopressor use. 16 In another study, 367 COVID-19 patients were diagnosed as having underlying NAFL/NASH based on past documentation or history of obesity along with elevated liver enzymes on 3 prior occasions. They found that the presence of NAFLD/NASH was associated with higher Odds for hospitalization. 19 The increased severity has also been documented in patients with fatty liver who are younger than 60 years of age. 22 So, it is evident that different studies have demonstrated association of fatty liver with a variety of severity defining parameters without any predetermined criteria for defining severity. In our study, we had predefined secondary outcome measures defining severity, such as COVID-19 CTSI score, Need for ICU admission, need for ventilatory support, length of hospital stay and length of ICU stay. Of these, only the CTSI score was found to be significantly higher among patients who had fatty liver. It was also found to be higher among those who had severe fatty liver as compared to those with mild or no fatty liver suggesting a strong association with presence & with degree of fatty liver. Radiological severity has also been highlighted by previous reports of COVID-19, in presence of underlying fatty liver. 6, 7 But even though the CTSI was found to be higher in patients with fatty liver, we could not demonstrate any association of fatty liver with clinical parameters of severity. Further, CTSI score was also not independently associated with mortality. Similar to our study, a few other studies have also not found any association of fatty liver with clinical outcomes in COVID-J o u r n a l P r e -p r o o f 19 patients. 18, 29 . Moreover, we feel that if the association of fatty liver with clinically severe disease was indeed a true association, then it should have also translated in to higher risk of mortality in the fatty liver group.

We also carried out analysis of factors associated with mortality. On multivariable analysis, high total leucocyte counts and high FIB-4 values were independently associated with mortality in the cohort of 446 patients. Targher One of the limitations of our study was its retrospective nature. We believe that the best study to answer the questions at hand would be a prospective study where known patients with proven NAFLD and those in whom NAFLD is excluded, develop COVID-19 and are then followed up. Such a study would be difficult to carry out because the patients need to be strictly isolated and cannot be subjected to the optimal tests. However, unlike previous studies we had standard definitions for fatty liver & COVID-19 pneumonia and specific criteria for outcomes (mortality and morbidity). Because of the retrospective nature of the study, we were also not able to have information on alcohol intake and markers for hepatitis B & C. So, the impact of etiology of fatty liver could not be studied. Although we have called these patients as fatty liver only, since they were picked up radiologically, but most of them can be presumed to have NAFLD. As mentioned earlier also, the non-invasive assessment of fibrosis in the setting of COVID-19 may not be a robust marker of liver fibrosis and its association with mortality may not be reliable. Finally, the sample size needed to J o u r n a l P r e -p r o o f detect a difference of 10% in mortality (our primary outcome measure) with a power of 80% and significance level 5% was 240 in each group. The study was planned to include these many cases in each group. However, the pandemic wave abated and we could not complete 240 cases in the non-fatty liver group . This was partially compensated by the increased number of cases with steatosis. With 289 cases and 157 controls, the power still was 76%.

In conclusion, we have demonstrated, in a case control study that fatty liver may not be associated with increased mortality or morbidity of patients who have COVID-19 pneumonia. 

Liver injury in COVID-19: management and challenges

Presenting characteristics, comorbidities and outcomes among 5700 patients, hospitalized with COVID-19 in the New York city area

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV 2 infection; The APCOLIS study (APASL COVID-19 Liver Injury Spectrum Study)

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: Multicentre matched cohort

Hepatic steatosis as an independent risk factor for severe disease in patients with COVID-19: A computed tomography study

The effect of hepatic steatosis on COVID-19 severity: Chest computed tomography findings

Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis

Risk of severe COVID-19 increased by metabolic dysfunction associated fatty liver disease: A meta-analysis

Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study

International consensus panel. MAFLD. A consensus driven proposed nomenclature for metabolic associated fatty liver disease

Hepatic steatosis index: a simple screening tool reflecting non-alcoholic fatty liver disease. Digestive and Liver Diseases

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection

Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings

Hepatic steatosis is associated with increased disease severity and liver injury in COVID-19

Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study

Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. medRxiv

Metabolic associated fatty liver disease is associated with severity of COVID-19

Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis

New-onset diabetes in COVID-19

Binding of SARS coronoavirus to its receptor damages islets and causes acute diabetes

Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations

Creactive protein and clinical outcomes in patients with COVID-19

CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard

-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID

Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience

Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multicentre study

Crosstalk between plasma cytokines, inflammation and liver damage as a new strategy to monitoring NAFLD progression

Association of pro-inflammatory cytokines , adipokines and oxidative stress with insulin resistance and nonalcoholic fatty liver disease

Chronic liver injury in rats and humans upregulates the novel enzyme antiotensin convertin enzyme 2

Duration ICU stay [Days

We are extremely grateful to Dr Abhaya Indrayan (Department of Biostatistics, Max Hospitals, Saket) for providing biostatistics support right from conceptualization to the final analysis of this study

Funding Source: None